ContraFect to Present at Cantor Antibiotics Summit
January 11 2018 - 7:00AM
ContraFect Corporation (NASDAQ:CFRX), a
clinical-stage biotechnology company focused on the discovery and
development of protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, today
announced that Steven C. Gilman, Ph.D., the Company's Chairman and
Chief Executive Officer, will participate in a panel discussion
entitled “Novel Ways to Treat and/or Address Infections” at the
Cantor Antibiotics Summit on Wednesday, January 17, 2018 at 12:15
PM ET in New York, NY. During the panel, Dr. Gilman will discuss
ContraFect’s development of first-in-class anti-infectives based on
the Company’s novel lysin technology.
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-resistant
Staphylococcus aureus) and influenza. The Company’s lead lysin,
CF-301, is currently being studied in a Phase 2 multicenter,
multinational, randomized, controlled clinical trial in patients
with Staphylococcal aureus (Staph aureus) bacteremia including
endocarditis. ContraFect is also conducting research focused on the
discovery of lysins to target Gram-negative bacteria.
About CF-301:
CF-301 is a recombinant bacteriophage-derived lysin with potent
bactericidal activity against Staph aureus, a major cause of blood
stream infections, or bacteremia. CF-301 has the potential to be a
first-in-class treatment for Staph aureus bacteremia. It has
a novel, rapid, and specific mechanism of bactericidal action
against Staph aureus and does not impact the body's natural
bacterial flora. By targeting a conserved region of the cell wall
that is vital to bacteria, resistance is less likely to develop to
CF-301. Combinations of CF-301 with standard of care antibiotics
significantly increased bacterial killing and survival in animal
models of disease when compared to treatment with antibiotics or
CF-301 alone. In addition, in vitro and in vivo experiments have
shown that CF-301 is highly active against biofilm infections.
CF-301 was licensed from The Rockefeller University and is being
developed at ContraFect. It is the first lysin to enter clinical
studies in the U.S.
Forward-Looking Statements
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our novel lysin
technology, our ability to discover and develop protein and
antibody therapeutics for life-threatening, drug-resistant
infectious diseases, our ability to address life threatening
infections using our therapeutic product candidates from our lysin
and monoclonal antibody platforms to target conserved regions of
either bacteria or viruses, whether our initial product candidates
can treat antibiotic-resistant infections such as MRSA
(Methicillin-resistant Staph aureus) and influenza, and our ability
to discover lysins targeting Gram-negative bacteria.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contact
Paul Boni ContraFect Corporation Tel: 914-207-2300
Email: pboni@contrafect.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024